Daiichi Sankyo's blood clot and stroke prevention drug, edoxaban, has met its primary efficacy endpoint in a phase three clinical trial. The clinical trial, ENGAGE, was evaluating the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback